Virtual Incision Appoints Jim Alecxih as Chief Executive Officer
LINCOLN, Neb.--(BUSINESS WIRE)-- Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, today announced the appointment of Jim Alecxih as chief executive officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System.
Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies.
Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide.
'The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,' said Jim Alecxih, CEO of Virtual Incision. 'I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, HOPD and ASC settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers.'
'We are delighted to welcome Mr. Alecxih to Virtual Incision at this significant stage in the company's growth,' said Tyler Stowater, partner at Bluestem Capital and Virtual Incision board member. 'Mr. Alecxih's exceptional leadership skills and deep industry knowledge make him the ideal person to lead us into our next phase of growth and innovation.'
Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards:
Fast Company's World's Most Innovative Companies
SXSW Innovation Award
Fierce MedTech's Fierce 15
Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery.
About the MIRA Surgical System
MIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready.
About Virtual Incision
Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn.
Important Safety Information
The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to www.virtualincision.com/safety-information.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Salmonella outbreak tied to pistachio cream imported from Turkey
Tubs of pistachio cream are being recalled after nearly half a dozen people reported becoming ill with salmonella infections, according to the Food and Drug Administration (FDA). Emek-brand Pistachio Cream — a product sold online for wholesale distributors, restaurants, and food service locations across the country — has been linked to a salmonella outbreak in at least two states, the FDA said. The product, a nut butter spread used in desserts, including ice cream, is manufactured by Emek Dogal Saglik Urunleri Iklim Gida Insaat San Tic Ltd Sti in Turkey and imported into the United States. The FDA and the Centers for Disease Control and Prevention (CDC), in collaboration with state and local partners, are investigating the multistate outbreak. As of May 19, four people, three of them in one north central state, reported becoming ill after eating the affected product, the FDA wrote in its updated June 13 post. The FDA said it is also working to determine whether "other lots or products from this firm may be impacted." Here's what to know about the cream recall: Tomato recall: Vegetable sold in 3 states now labeled deadly by FDA So far, people in two states have reported being sickened from the product, according to the FDA and the CDA. Minnesota (three people) New Jersey (one person) The FDA is recalling some Emek-brand Pistachio Cream packaged in a 5-kilogram white tub. The recalled cream has a use-by date of Oct. 9, 2026, and the production code (PNO:) of 241019. According to its online post, the FDA was notified by the Minnesota Department of Health about "a cluster of Salmonella illnesses and two Salmonella positive samples of Emek-brand Pistachio Cream product that matched clinical cases by whole genome sequencing (WGS) in this outbreak." As of June 13, four cases of salmonella infection had been reported from two states. Of those cases, all four reported eating pistachio cream, the FDA said, and three of the four cases reported eating pistachio cream at the same restaurant. One of the individuals who consumed the affected cream had to be hospitalized, the FDA said. Salmonella is an organism that can cause serious and fatal infections in children, the elderly and others with weakened immune systems, according to the CDC. Most people infected with salmonella start developing symptoms 12 to 72 hours after eating the contaminated product. Diarrhea, fever and abdominal cramps are the main symptoms. Most people recover without treatment, but in rare circumstances, the infection can require hospitalization, according to the CDC. Pregnant women are also at higher risk of developing an infection from it and should seek medical attention if symptoms arise. Consumers experiencing an illness because of the affected product should contact their health care provider to report their symptoms and for medical care. Natalie Neysa Alund is a senior reporter for USA TODAY. Reach her at nalund@ and follow her on X @nataliealund. This article originally appeared on USA TODAY: Pistachio cream recalled after being linked to salmonella outbreak
Miami Herald
an hour ago
- Miami Herald
How Recall of 20 Million Eggs Could Affect US Prices
The recent salmonella-linked recall of 1.7 million dozen (20.4 million) eggs could drive prices significantly higher, according to one expert. "This is not good news," North Carolina State University economist Mike Walden told Newsweek. "Lower egg supply will increase egg prices." Walden estimated that the recall could see prices rise by 25 percent across the affected regions. The price of eggs, already seen by many as a barometer of inflation, has become a political flashpoint this year. President Donald Trump blamed the increase on Joe Biden's policies before taking credit for the more recent price plunge. Widespread outbreaks of avian flu took a significant toll on production, leading to nationwide shortages and pushing prices up to record highs. While far more contained, the latest recall, prompted by fears over salmonella contamination and impacting nine states, could offset some of the declines in cost that have been seen since March. On June 6, August Egg Company announced a voluntary recall of the brown cage-free and certified organic brown eggs over fears of salmonella contamination. According to the U.S. Food and Drug Administration (FDA), the eggs were sold by multiple brands, including Walmart, between February and May across nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington and Wyoming. The Centers for Disease Control and Prevention (CDC) said the eggs could be tied to the salmonella outbreak that has infected 79 people so far this year, and that FDA inspections at the August Egg Company found that samples of salmonella found in the eggs were "closely related" to those seen in the human cases. "The true number of sick people in this outbreak was likely much higher than the number reported," the CDC said, "and this outbreak may not have been limited to the states with known illnesses." Joseph Balagtas, professor of agricultural economics at Purdue University, told Newsweek that the impact of the recall on prices would likely be limited, given the 20.4 million affected eggs represent "tiny fraction" of the more than 8 billion produced each month. For context, he said that the price spikes earlier this year were a result of an egg production shortfall of about 1 billion because of outbreaks of highly pathogenic avian influenza (HPAI) in February. He added that any noticeable upward pressure on prices would likely be masked by the recent decline in the cost of eggs in the U.S. According to the Consumer Price Index reading released by the Bureau of Labor Statistics last week, egg prices dropped 2.7 percent in May, following a 12.7 percent decline in April. However, prices are still up 41.5 percent from the same time last year. August Egg Company, in its recall announcement: "It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens. "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring. We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again." Joseph Balagtas, professor of agricultural economics at Purdue University, told Newsweek: "By removing eggs from the market, the recall will put some upward pressure on prices. But I expect the magnitude of the price effect to be small, perhaps imperceptible in the context of day-to-day fluctuations in prices." August Egg Company said that it has stopped selling fresh shell eggs for the time being and urged consumers to return those with the plant code numbers listed in its recall to the place they were purchased for a full refund. The plant code numbers for the recalled eggs can be found printed on the package and are P-6562 or CA5330 with Julian Dates from 32 to 126, the FDA said. The Julian Dates are codes of three to seven digits and represent the date that the food was packaged or manufactured. Related Articles Egg Recall Map Shows Warnings Issued to Customers in 9 StatesThese Hungry Animals Eat Their First Meal Before BirthEgg Prices PlungeBread Recall Issued Over Life-Threatening Reaction Warning 2025 NEWSWEEK DIGITAL LLC.
Yahoo
an hour ago
- Yahoo
Exo Launches a New Era in Disease Diagnosis with the First FDA-cleared Ultrasound AI for Detection of Pleural Effusion and Consolidation/Atelectasis
Exo Iris® now automatically detects and localizes key pulmonary findings for emergency care, showing superiority to clinicians alone SANTA CLARA, Calif., June 18, 2025--(BUSINESS WIRE)--Exo (pronounced "echo"), the leader in AI-powered, accessible medical imaging, is transforming lung disease diagnosis with another first. Now included on Exo Iris® is the first ever FDA 510(k) cleared AI for detecting pleural effusion and consolidation/atelectasis. These on-device real-time indicators empower clinicians with objective data to help detect lung diseases like pneumonia and tuberculosis at the bedside in seconds. Arun Nagdev, MD, Vice President of Clinical Affairs at Exo and a leading POCUS expert, said, "This groundbreaking real-time AI provides a remarkable assist for all clinicians at the bedside, instantly and accurately detecting fluid around the lungs or areas of collapsed lung, key markers for significant infections like pneumonia or tuberculosis. This is a great support for clinicians looking to diagnose commonly presenting patient symptoms of shortness of breath, coughing, pain, and fatigue." Said Dornoosh Zonoobi, VP of AI at Exo, "Validated in rigorous clinical studies, these AIs enabled clinicians to detect key lung findings, with sensitivity and specificity in the 'excellent' range. We're thrilled to bring these FDA-cleared firsts to all clinicians and to meaningfully impact patient diagnosis and outcomes when it matters most." These clearances mark not only a technical and regulatory milestone, but a meaningful expansion in how Exo is supporting frontline providers and patients when every second counts. Exo remains focused on delivering technology that enables critical decisions instantly, intelligently, and saves lives at scale. These clearances bring to a remarkable 14, the FDA-cleared AI indicators embedded in Iris. This sweeping portfolio is unmatched in handheld ultrasound today. All commercialized Exo AI runs directly on Exo Iris®, operates without internet, eliminates lag, and enables expert-level diagnostics in any setting. Exo is establishing a new standard in fast, accurate, and scalable point-of-care imaging. Visit Exo's website to explore these capabilities. About Exo Exo is redefining medical imaging with its advanced ultrasound platform, combining novel silicon-based hardware, tightly coupled AI, and easy-to-use collaboration software. Its handheld and soon-to-be OEM-integrated systems deliver high-performance imaging and real-time clinical intelligence, driving better, more accessible diagnostics and outcomes across diverse care settings. Follow us at @exoeffect on X, LinkedIn, Facebook, and Instagram. View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
